Summarized by Masters of Longevity from Longevity Technology.
CTAD will show 76‑ and 96‑week efficacy, biomarker, and safety data for diranersen.
Key Takeaways
- Diranersen is an ASO that lowers all forms of tau.
- CELIA enrolled 416 people with early Alzheimer’s disease.
- Ninety‑six week results are pending and remain unproven.
